When evaluating 23andMe's stock performance and future outlook, investors should consider short-term market trends and long-term growth potential. This analysis will dive into recent stock metrics, price forecasts and key indicators that can shape a company's future stock price movements.
Current Overview of 23andMe Stock
23andMe Holding Co. is currently trading with a market capitalization of $82.05 million, reflecting its position as a smaller player in the genetic testing market. The stock's trading volume sits at 231,031, showing moderate interest from investors, while the stock price has fluctuated significantly. With a P/E ratio of -0.10, the company is not currently profitable, which may raise concerns for risk-averse investors. The stock's beta of -5.25 indicates volatility, meaning it tends to move more sharply than the broader market, a factor that traders should watch closely.
Methodology for Stock Price Prediction
To forecast the future price of 23andMe stock, analysts use a combination of technical analysis, consensus ratings and market data. Analysts assign normalized scores to help categorize a stock's rating, ranging from strong sell to strong buy. These ratings, combined with key support and resistance levels, help to project how the stock might perform under various market conditions. Price targets are also derived from analysts’ reports, providing investors with insight into potential future stock value. By evaluating 23andMe's historical price trends, company developments and broader market movements, analysts can make more informed stock price predictions.
23andMe Stock Price Prediction for 2024
The stock price prediction for 23andMe Holding Co. reflects cautious optimism. Analysts suggest that the stock could experience price fluctuations, with support and resistance levels playing a crucial role in dictating short-term trends. With the current stock price at $3.41, analysts predict a possible price range from $0.32 to $0.38 over the last few weeks of December, influenced by the company’s financial performance and broader market conditions. Investor sentiment remains mixed, as the stock holds a "Reduce" consensus rating based on recent analyst recommendations.
23andMe Stock Price Prediction for 2025
Looking ahead to 2025, 23andMe’s stock could see moderate growth, though it remains subject to market volatility and the company’s ability to drive innovation. The current analyst consensus rating suggests a price target of $4.72, representing a potential upside of approximately 38.42% from the current price. With one analyst recommending a hold and another suggesting a sell, the forecast for 2025 remains uncertain. Traders are encouraged to monitor the company’s support and resistance levels to gain insights into its likely performance throughout the year.
23andMe Stock Price Prediction for 2030
By 2030, 23andMe’s stock price could be shaped by its advancements in genetic testing technology and market growth. While current short-term forecasts suggest a price range between $2.68 and $8.78, future performance could improve significantly if the company successfully expands its product offerings and captures more market share. Long-term stock price predictions are speculative, but the market expects slow and steady growth as genetic testing becomes more widespread and accessible.
Is 23andMe Stock Right For You?
Whether 23andMe stock is a good investment depends on your risk tolerance and investment strategy. The stock’s recent downgrade from a buy to a hold/accumulate rating reflects technical weaknesses and positive signals. While 23andMe has potential for future growth, particularly if it can innovate within the genetic testing space, its current financial challenges and volatility may make it a more suitable option for risk-tolerant investors.
Agree with these predictions? Trade futures on this stock with Plus500 in the US and CFDs internationally. Sign up now for a $200 bonus.*
Frequently Asked Questions
What is the future growth of 23andMe?
23andMe is expected to grow slowly as it continues to innovate within the genetic testing market.
Is 23andMe a good investment?
It may be a good investment for risk-tolerant investors, but the company faces financial challenges.
What is the price prediction for 23andMe stock?
The stock is forecasted to reach $4.72 in 2025, reflecting a nearly 38% potential upside from the current price of $3.41.
* Plus500 is a Benzinga Partner and the promotion of this offer was sponsored by the Partner. This does not impact the content at all.